ADC Therapeutics SA (ADCT)
| Market Cap | 476.96M |
| Revenue (ttm) | 81.36M |
| Net Income (ttm) | -142.62M |
| Shares Out | 127.19M |
| EPS (ttm) | -1.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 439,252 |
| Open | 3.750 |
| Previous Close | 3.760 |
| Day's Range | 3.720 - 3.835 |
| 52-Week Range | 1.225 - 4.980 |
| Beta | 1.95 |
| Analysts | Strong Buy |
| Price Target | 7.75 (+106.67%) |
| Earnings Date | May 4, 2026 |
About ADCT
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue... [Read more]
Financial Performance
In 2025, ADC Therapeutics's revenue was $81.36 million, an increase of 14.85% compared to the previous year's $70.84 million. Losses were -$142.62 million, -9.64% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ADCT stock is "Strong Buy." The 12-month stock price target is $7.75, which is an increase of 106.67% from the latest price.
News
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th...
ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha...
ADC Therapeutics Transcript: H.C. Wainwright Home Series
ZYNLONTA is positioned for significant growth, with pivotal LOTIS-5 and LOTIS-7 trial data expected in 2024. Expansion into second-line DLBCL and indolent lymphomas could drive peak sales to $600M–$1B, supported by a strong cash position and strategic flexibility.
ADC Therapeutics Earnings Call Transcript: Q4 2025
ZYNLONTA revenues grew in Q4 2025, with stable annual sales and reduced operating expenses. Strategic focus on expanding indications and strong cash position support long-term growth, with key clinical data readouts expected in 2026 and 2027.
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty financing agreement increases s...
ADC Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
ZYNLONTA is positioned for significant growth with pivotal phase III and combination study data expected this year, targeting both complex and broadly accessible DLBCL segments. Early results show high response rates and manageable safety, with expansion into indolent lymphomas and second-line settings projected to drive revenue growth to $600 million–$1 billion.
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha...
ADC Therapeutics to Participate in March Investor Conferences
LAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced par...
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha...
ADC Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Zynlonta is expanding from third line DLBCL into earlier lines and indolent lymphomas, with pivotal LOTIS-5 and LOTIS-7 trials expected to drive significant revenue growth from 2027. Strong efficacy, rapid response, and a favorable safety profile position it competitively in both complex and broadly accessible therapy segments.
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately $261M as of December 31, 2025, provi...
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics Transcript: Study Update
Updated LOTIS-7 data show ZYNLONTA plus glofitamab achieved an 89.8% ORR and 77.6% CR rate in second-line plus DLBCL, with durable responses and a manageable safety profile. Lower CRS rates and strong efficacy in relapsed and refractory patients support further development.
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up Combination continues to be...
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
Company to host corporate webcast to share updated data on December 3, 2025 LAUSANNE, Switzerland , Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and ...
ADC Therapeutics Transcript: Jefferies London Healthcare Conference 2025
ZYNLONTA maintains a stable 10% share in third-line DLBCL, with strong efficacy and safety. Key trials (LOTIS-5 and LOTIS-7) aim to expand indications and market size, targeting up to $800M in combined opportunities. Cash runway extends into 2028.
ADC Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
ZYNLONTA is positioned for growth in DLBCL with strong academic and community support, targeting both broadly accessible and complex therapy segments. Key trials (LOTIS-5 and LOTIS-7) are progressing, with promising efficacy and safety data, and additional opportunities in indolent lymphomas and pipeline assets.
ADC Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 net product revenues were $15.8M, with operating expenses down 12.1% year-over-year. Key clinical trials (LOTIS-5, LOTIS-7) are progressing, and a $60M financing extends cash runway to 2028. ZYNLONTA's market potential is estimated at $600M–$1B in peak annual U.S. revenue.
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026 Updated data from Phase 2 IIT of ZYNLONTA® plus rituximab in patients with r/...
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
LAUSANNE, Switzerland , Nov. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha...
ADC Therapeutics to Present at November Investor Conferences
LAUSANNE, Switzerland , Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced pa...
ADC Therapeutics Announces $60 Million Private Placement
LAUSANNE, Switzerland , Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th...
ADC Therapeutics Transcript: Cantor Global Healthcare Conference 2025
ZYNLONTA is being advanced as a potential new standard in DLBCL, with strong efficacy and safety data from LOTIS-5 and LOTIS-7 trials. High response rates in indolent lymphomas and a robust cash position support multiple upcoming catalysts through 2027.
ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025
LAUSANNE, Switzerland , Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th...